Biologic therapies for the treatment of psoriatic arthritis

Psoriatic arthritis: treatment strategies using biologic agents.

The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently available anti-TNFα blocking agents (etanercept, infliximab, adalimu...

Biologic therapy of psoriatic arthritis.

Psoriatic arthritis is now recognized as a potentially serious and disabling disease. Traditional therapies have not been very effective in controlling signs and symptoms or preventing progression of damage. Based on the pathogenesis of the disease new therapies have been introduced, particularly anti-TNF agents and anti-T cell agents. Several of those have shown excellent responses in clinical...

Biologic therapies for juvenile arthritis.

A group of therapies with exciting potential has emerged for children and young people with severe juvenile idiopathic arthritis (JIA) uncontrolled by conventional disease modifying drugs. Theoretical understanding from molecular biologic research has identified specific targets within pathophysiological pathways that control rheumatoid arthritis (RA) and JIA. This review identifies the pathway...

Treatment Persistence With Subcutaneous Biologic Therapies in Patients With Psoriatic Arthritis (Psa).

Background • Psoriatic arthritis (PsA) is an inflammatory peripheral and/or axial arthritis associated with psoriasis, usually seronegative for rheumatoid factors1 • Patients with PsA also have debilitating skin disease, and nearly half may also have a spinal disease.2 PsA is estimated to affect 2.0% to 3.0% of the general population3 • To date, few studies have examined treatment persistence o...

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.